United Therapeutics Corporation (NASDAQ:UTHR) Receives Consensus Rating of “Moderate Buy” from Brokerages

United Therapeutics Corporation (NASDAQ:UTHR) has been assigned an average recommendation of “Moderate Buy” from the eleven analysts that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $509.50.

A number of equities research analysts have issued reports on UTHR shares. UBS Group increased their target price on shares of United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research report on Tuesday. Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a research note on Wednesday, October 29th. Jefferies Financial Group reiterated a “buy” rating and set a $575.00 price objective on shares of United Therapeutics in a report on Wednesday, November 19th. Wells Fargo & Company lifted their price objective on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th.

United Therapeutics Trading Down 2.6%

Shares of NASDAQ UTHR opened at $490.83 on Friday. United Therapeutics has a one year low of $266.98 and a one year high of $519.99. The business has a 50-day moving average price of $483.18 and a two-hundred day moving average price of $400.13. The firm has a market capitalization of $21.14 billion, a PE ratio of 18.60, a PEG ratio of 2.61 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. The business had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm’s revenue was up 6.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.39 earnings per share. Research analysts anticipate that United Therapeutics will post 24.48 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $485.43, for a total transaction of $4,029,069.00. Following the transaction, the executive vice president owned 36,781 shares in the company, valued at $17,854,600.83. This represents a 18.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jan Malcolm sold 50 shares of the firm’s stock in a transaction on Tuesday, December 23rd. The shares were sold at an average price of $512.12, for a total transaction of $25,606.00. Following the transaction, the director owned 420 shares in the company, valued at $215,090.40. This represents a 10.64% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 608,514 shares of company stock worth $284,376,421 in the last quarter. Corporate insiders own 10.30% of the company’s stock.

Institutional Trading of United Therapeutics

Several large investors have recently modified their holdings of the company. Chung Wu Investment Group LLC bought a new position in United Therapeutics in the 2nd quarter worth $29,000. WealthCollab LLC grew its position in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. increased its stake in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the period. Wilmington Savings Fund Society FSB increased its stake in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the period. Finally, Abich Financial Wealth Management LLC acquired a new position in shares of United Therapeutics during the 3rd quarter worth about $44,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.